Institution
University of Queensland
Education•Brisbane, Queensland, Australia•
About: University of Queensland is a education organization based out in Brisbane, Queensland, Australia. It is known for research contribution in the topics: Population & Poison control. The organization has 51138 authors who have published 155721 publications receiving 5717659 citations. The organization is also known as: UQ & The University of Queensland.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: The molecular basis of SARS-CoV-2 RNA replication is examined by determining the cryo-EM structures of the stalled pre-/post- translocated polymerase complexes and the inhibition mechanisms of the triphosphate metabolite of remdesivir are investigated through structural and kinetic analyses.
617 citations
••
TL;DR: The elements required to generate myeloid- and trophoblast-specific transgenes as well as a model system for the study of mononuclear phagocyte development and function are defined.
617 citations
••
TL;DR: This study shows that specifically blocking PD-1 immunosuppression can potently enhance CAR T-cell therapy that has significant implications for potentially improving therapeutic outcomes of this approach in patients with cancer.
Abstract: Purpose: To determine the antitumor efficacy and toxicity of a novel combination approach involving adoptive T-cell immunotherapy using chimeric antigen receptor (CAR) T cells with an immunomodulatory reagent for blocking immunosuppression.
Experimental Design: We examined whether administration of a PD-1 blocking antibody could increase the therapeutic activity of CAR T cells against two different Her-2+ tumors. The use of a self-antigen mouse model enabled investigation into the efficacy, mechanism, and toxicity of this combination approach.
Results: In this study, we first showed a significant increase in the level of PD-1 expressed on transduced anti-Her-2 CD8+ T cells following antigen-specific stimulation with PD-L1+ tumor cells and that markers of activation and proliferation were increased in anti-Her-2 T cells in the presence of anti-PD-1 antibody. In adoptive transfer studies in Her-2 transgenic recipient mice, we showed a significant improvement in growth inhibition of two different Her-2+ tumors treated with anti-Her-2 T cells in combination with anti-PD-1 antibody. The therapeutic effects observed correlated with increased function of anti-Her-2 T cells following PD-1 blockade. Strikingly, a significant decrease in the percentage of Gr1+ CD11b+ myeloid-derived suppressor cells (MDSC) was observed in the tumor microenvironment of mice treated with the combination therapy. Importantly, increased antitumor effects were not associated with any autoimmune pathology in normal tissue expressing Her-2 antigen.
Conclusion: This study shows that specifically blocking PD-1 immunosuppression can potently enhance CAR T-cell therapy that has significant implications for potentially improving therapeutic outcomes of this approach in patients with cancer. Clin Cancer Res; 19(20); 5636–46. ©2013 AACR .
See related article by Morales-Kastresana, et al., [p. 5546][1]
This article is featured in Highlights of This Issue, [p. 5543][2]
[1]: /lookup/volpage/19/5546?iss=20
[2]: /lookup/volpage/19/5543?iss=20
616 citations
••
TL;DR: These findings suggest that longer ncRNAs are under the influence of different evolutionary constraints and that the lack of conservation displayed by the thousands of candidate nc RNAs does not necessarily signify an absence of function.
614 citations
••
TL;DR: Honeycomb catalysis: a facile oxygen reduction reaction has been observed on a graphitic C(3)N(4)/carbon catalyst with three-dimensional interconnected macropores with much higher organic-fuel tolerance and long-term stability.
Abstract: Honeycomb catalysis: a facile oxygen reduction reaction has been observed on a graphitic C(3)N(4)/carbon catalyst with three-dimensional interconnected macropores (see picture with SiO(2) template). This material not only shows catalytic activity that is comparable to that of commercial Pt/C, but also has much higher organic-fuel tolerance and long-term stability.
613 citations
Authors
Showing all 52145 results
Name | H-index | Papers | Citations |
---|---|---|---|
Graham A. Colditz | 261 | 1542 | 256034 |
George Davey Smith | 224 | 2540 | 248373 |
David J. Hunter | 213 | 1836 | 207050 |
Daniel Levy | 212 | 933 | 194778 |
Christopher J L Murray | 209 | 754 | 310329 |
Matthew Meyerson | 194 | 553 | 243726 |
Luigi Ferrucci | 193 | 1601 | 181199 |
Nicholas G. Martin | 192 | 1770 | 161952 |
Paul M. Thompson | 183 | 2271 | 146736 |
Jie Zhang | 178 | 4857 | 221720 |
Alan D. Lopez | 172 | 863 | 259291 |
Ian J. Deary | 166 | 1795 | 114161 |
Steven N. Blair | 165 | 879 | 132929 |
Carlos Bustamante | 161 | 770 | 106053 |
David W. Johnson | 160 | 2714 | 140778 |